Referencias: guía detallada del cáncer de piel tipo melanoma

American Academy of Pediatrics. Policy statement – Ultraviolet radiation: A hazard to children and adolescents. Pediatrics. 2011;127:588–597.

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Joint Committee on Cancer. Melanoma of the skin. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:325–344.

Berman B, Villa AM. Immune response modulators in the treatment of skin cancer. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:499–513.

Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 2. [Epub ahead of print]

Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. New Engl J Med. 2005;353:2135–2147.

Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–5239.

El Ghissassi, Baan R, Straif K, et al. A review of human carcinogens--part D: Radiation. Lancet Oncol. 2009;10:751–752.

Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jun 4. [Epub ahead of print]

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 June 25. [Epub ahead of print]

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Huang CL, Halpern AC. Management of the patient with melanoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:265–273.

Lange JR, Fecher LA, Sharfman WH, et al. Melanoma. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1229–1252.

Leachman SA, Lowstuter K, Wadge LM. Genetic testing for melanoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:281–290.

National Cancer Institute. Physician Data Query (PDQ). Melanoma Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional on June 26, 2012.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma. Version 3.2012. Accessed at www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf on June 26, 2012.

Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: A meta-analysis of pigmentary characteristics and freckling. Int J Cancer. 2010;127:2430–2445.

Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–924.

Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol. 2009;27:18s (suppl; abstr CRA9011).

Slingluff CL, Flaherty K, Rosenberg SA, Read PW. Cutaneous melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1643–1691.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 2. [Epub ahead of print]